Addressing Lung Cancer Biomarker Testing Through Project ECHO in Georgia: Orientation Session 0 6.9.2021 Welcome to the Orientation Session of the Addressing Lung Cancer Biomarker Testing Through Project ECHO in Georgia Addressing Lung Cancer Biomarker Testing Through Project ECHO Each ECHO session will be recorded and may be posted to a publicly-facing website You will be muted with your video turned off when you join the call. Use the buttons in the black menu bar to unmute your line and to turn on your video. If you do not wish to have your image recorded, please turn OFF the video option. Today’s materials will be made available on our ACS ECHO website Please type your name and organization in the chat box This ECHO session takes place on the Zoom platform. To review Zoom’s privacy policy, please visit zoom.us/privacy Remember: Do NOT share any personal information about any patient Questions about Zoom? Type them in the chat box @dionnechristopher This project is funded partially though Amgen Oncology and Foundation Medicine Please type your name and organization in the chat box Have a question? Don’t wait to ask! Feel free to enter in the “Chat” at anytime. Today’s Agenda 01 Welcome and Housekeeping (5 minutes) 02 ECHO Hub and Spoke Introductions (10 minutes) 03 Project Goals & Introduction to the ECHO Model (10 minutes) 04 The Burden of Lung Cancer in Georgia (5 minutes) 05 Introduction to Lung Cancer Biomarker Testing (15 minutes) 07 Open Discussion/Q&A (10 minutes) 08 Wrap Up (5 minutes) GEORGIA ORIENTATION: SESSION 0 Adam Jones, MD Oncology, Radiation Oncology Phoebe Putney Health System Radiation Oncology Associates ECHO Hub & Spoke Chair Introductions Georgia Lung Cancer Roundtable Disclosures ‒ No disclosures to report Context-Setting This project will elevate the quality of lung cancer treatment and outcomes across Georgia and our region Some patient do NOT have access to biomarker testing which can affect their treatment regimen and recommendations The landscape of lung cancer treatment has shifting dramatically in the past decade Targeted therapies have been developed that specifically identify and neutralize growth of cancer cells Targeted agents are effective and generally better tolerated than chemotherapy Biomarker testing saves lives, multiple publications and guidelines (including NCCN) have emerged along with the FDA approval of many new agents Georgia Specific Goals Through web-based didactic presentations and interactive case discussions ‒ Build relationships between academic institutions, spoke sites, and cancer centers across the state ‒ Create dialogue and educational opportunities that results in increased utilization of appropriate biomarker testing in the diagnostic evaluation and management of lung cancer Introductions: Meet our Georgia ECHO Hub Eric Flenaugh, MD, FCCP Adam Jones, MD Suresh Ramalingam, MD, FASCO Grady Health System Phoebe Putney Health System Winship Cancer Institute & Emory University Faculty Member Facilitator & Faculty Member School of Medicine Faculty Member Jessica Davis Dionne Christopher American Cancer Society American Cancer Society ECHO Coordinator ECHO Tech Coordinator Introductions: Meet our Seven Georgia Spoke Sites One Person from Each Spoke Site to Briefly Say Hello GEORGIA ORIENTATION: SESSION 0 Jessica Davis Project Goals & Introduction Senior Manager, Cancer Control Strategic Partnerships to the ECHO Model American Cancer Society ECHO SERIES PROJECT GOALS SPOKES/LEARNERS WILL GAIN THE STATE-BASED ECHO PROVIDE VALUABLE INSIGHTS KNOWLEDGE AND CONFIDENCE APPROACH WILL FOSTER FOR PILOT REPLICATION COLLABORATION ‒ to address the common ‒ Evaluate and apply learned barriers that may exist within ‒ to address the more common lessons to improve the model their institutions in the lung barriers related to biomarker that will enable successful cancer biomarker space testing within Georgia, replication in other pilot states reflective of its unique cultural, in 2022 ‒ to help implement biomarker geographic, and payer testing in NSCLC successfully at landscape their institutions First Three Pilot Locations: Georgia, Kentucky, and Mississippi ECHO Participation Poll Today’s Session will NOT serve as a typical ECHO session but instead will function more like a traditional interactive webinar About Project ECHO ‒ ECHO effectively and efficiently disseminates evidence-based strategies to improve cancer outcomes ‒ ECHO serves as a hub-and-spoke knowledge led by expert teams (faculty) who utilize videoconferencing (Zoom) to conduct virtual clinics with participants (learners and spokes) ‒ ECHO is a proven one-to-many intervention The American Cancer Society serves as a Project ECHO (Extension for Community Healthcare Outcomes) Hub Expectations of Participating Spoke Sites ‒ Build a small multidisciplinary ECHO team from your system or center ‒ Have at least one team member join each monthly one-hour ECHO session ‒ Deliver (as a team) one case presentation over the course of the ECHO Series ‒ Complete the post-session poll questions ‒ Complete the three survey/assessments Reminder: If you have not already, please COMPLETE the Pre-ECHO Assessment. The email was sent from the ACS ECHO Office on 6/4/2021. What to Expect: The Anatomy of an ECHO Session ‒ Housekeeping and Introductions (10 min) ‒ Didactic Presentation (15 min) ‒ Didactic Q/A (5 min) ‒ Case Presentation(s) (3-5 min) ‒ Case Presentation(s) Discussion/Guidance (20 min) ‒ Wrap Up & Post-Session Survey Poll (5 min) For more about the ECHO Model or Project ECHO, please visit www.echo.unm.edu Note: The Case Presentation Form is “Living” Document The Case Presentation Process Spokes will submit their Faculty will receive the case The case presentation case presentation forms presentation at least 48 The ACS ECHO Coordinator does NOT have to be at least three business hours in advance and can will type the key takeaways thematic to the didactic days prior to the ECHO provide advance written and recommendations, presentation (while it may session. The case feedback and or verbal which will be sent out to in improve the session flow). presentation form serves feedback during the ECHO the post-session recap. as the sole requirement. session. Additional slides are optional. Case presentations are the heart of the ECHO model, ensuring that “everyone teaches, everyone learns” Ready to Schedule your Case Presentation? Two Convenient Ways 1. Email Jessica Davis and Kelly Durden with your preferred Case case presentation date (choose Presentation! between the Georgia specific or the combined sessions) Or 2. Complete our simple Case Presentation Interest Survey A member of the ACS Hub team will confirm your case presentation date and work with you to ensure your experience is easy AND valuable. All meeting materials, including the case presentation notes, will be disseminated and uploaded within one week of the session Addressing Comprehensive Lung Cancer Biomarker Testing Through Project ECHO Pilot Series: Georgia Monthly ECHO Session Didactics Session 0 Orientation to the Comprehensive Lung Cancer Biomarker Testing ECHO Series State-Based 6/9/2021 Not a traditional ECHO, will operate more like an interactive webinar Georgia ONLY 12 PM to 1 PM ET Session 1 Understanding the Barriers to Biomarker Testing Combined 6/28/2021 M. Patricia Rivera, MD, ATSF, FCCP 1 ECHO for All 3 Pilot States 2 PM to 3 PM ET University of North Carolina at Chapel Hill Session 2 Pathways to Biomarker Testing State-Based 7/21/2021 Suresh Ramalingam, MD, FASCO Georgia ONLY 12 PM to 1 PM ET Emory University/Winship Cancer Institute Session 3 Adequate Tissue for Sampling 8/26/2021 Gerard A. Silvestri, MD, MS, FCCP Combined 1 PM to 12 PM ET Medical University of South Carolina Session 4 Choice of Panel, Interpretation of Results, and Next Steps 9/23/2021 Ignacio I. Wistuba, MD Combined 1 PM to 2 PM ET The University of Texas MD Anderson Cancer Center Session 5 Improving Turnaround Time 10/19/2021 Lynette M. Sholl, MD, FCAP Combined 1 PM to 2 PM ET Dana-Farber/Harvard Cancer Center Session 6 What's Covered: Reimbursement and Coverage Policies from the Private and Public State-Based 11/10/2021 Payer Landscape Georgia ONLY 12 PM to 1 PM ET TBD Session 7 Tentative Topic State-Based 12/8/2021 Current and Future Biomarker-Driven Treatment Options for NSCLC Georgia ONLY 12 PM to 1 PM ET (FDA Approved or Cancer clinical trials when no FDA approved treatment exists) GEORGIA ORIENTATION: SESSION 0 Eric Flenaugh, MD, FCCP Director of Advanced Diagnostic Interventional Pulmonary Medicine The Burden of Lung Cancer Lung Nodule Clinic Physician Director in Georgia Grady Health System Disclosures ‒ No disclosures to report Lung Cancer Burden At a Glance Nearly Only 2 1 16% 1 in 4 of Lung Cancer Cases of all Cancer Deaths are Diagnosed in an are From Lung Cancer Early Stage * 1American Cancer Society. Cancer Facts and Figures. Cancer.org. [Online] 2019. https://www.cancer.org/latest-news/facts-and-figures-2019.html 2 US National Institute of Health, National Cancer Institute.SEER Cancer Statistics Review, 1975-2015. Lung Cancer Burden At a Glance in Georgia 7,250 4,200 62.8 40.9 Estimated New Estimated Deaths Incidence rates, Death rates, Cases in 2021 in 2021 2013-2017* 2014-2018** *Average annual rate per 100,000, age **Average annual. rate per 100,000, adjusted to the 2000 US standard age adjusted to the 2000 US population standard population. Rates for PR are for 2012-2016 Data sources: North American Association of Central Data sources: National Center for Health Statistics (NCHS), Cancer Registries (NAACCR), 2020 Centers for Disease Control and Prevention, 2020 Source: American Cancer Society, Cancer Statistic Center Source: American Lung Association, State of Lung Cancer 2020 Data Set Sources & Definitions ‒Mortality Rates: 2014-2018 ‒Incidence Rates: 2013-2017 ‒Late-stage Incidence Rates: 2013-2017 ‒NCI, CoC hospitals and ACR screening locations: Geocoded in 2020 ‒Surveillance data accessed in April 2021 from the cancer state profile ‒Rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population ‒Rates are for invasive cancer only ‒Rates calculated using SEER*Stat.